AIP
GILD icon

Arrowpoint Investment Partners’s Gilead Sciences GILD Stock Holding History

Arrowpoint Investment Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.67M Sell
11,961
-7,458
-38% -$1.04M 1.48% 17
2025
Q4 		$2.38M Buy
+19,419
New +$2.36M 0.35% 22

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Arrowpoint Investment Partners's GILD Position: Q1 2026 in Review

Arrowpoint Investment Partners reduced its Gilead Sciences (GILD) stake by 38% in Q1 2026, selling an estimated $1.04M and leaving 11,961 shares worth $1.67M. The position accounts for 1.48% of the portfolio, ranked #17.

Arrowpoint Investment Partners first reported a position in GILD in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.38M in Q4 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Arrowpoint Investment Partners held 11,961 shares of Gilead Sciences worth $1.67M as of Q1 2026.
  • Arrowpoint Investment Partners sold 7,458 Gilead Sciences shares in Q1 2026, an estimated $1.04M.
  • Gilead Sciences made up 1.48% of Arrowpoint Investment Partners's portfolio in Q1 2026, its #17 holding.
  • Arrowpoint Investment Partners first reported a position in Gilead Sciences in Q4 2025 and has held it in 2 quarters since.
  • Arrowpoint Investment Partners's Gilead Sciences position peaked at $2.38M in Q4 2025.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.